Role of hematopoietic cell transplantation for myeloma Book Section
| Authors: | Landau, H.; Giralt, S. |
| Editors: | Wiernik, P. H.; Dutcher, J. P.; Gertz, M. A. |
| Article/Chapter Title: | Role of hematopoietic cell transplantation for myeloma |
| Abstract: | It has been more than 30 years since McElwain and Powles demonstrated the benefits of high-dose melphalan in the treatment of relapse and refractory myeloma. With autologous hematopoietic cell support high-dose melphalan has become the best available strategy to achieve high CR rates and prolong PFS as consolidation of a proteosome inhibitor, immune-modulatory drug, and steroid induction therapy. However, the best timing of HCT remains an area of active debate and major interest with most ongoing clinical trials showing progression-free survival benefit and some showing survival benefit. Although significant advances have been made in myeloma therapy no major changes have occurred in the setting of high-dose melphalan therapy. In this chapter we review current status and future directions of high-dose therapy for myeloma. © Springer International Publishing AG 2018. |
| Keywords: | melphalan; myeloma; hematopoietic cell transplantation |
| Book Title: | Neoplastic Diseases of the Blood. 6th ed |
| ISBN: | 978-3-319-64262-8 |
| Publisher: | Springer |
| Publication Place: | Cham, Switzerland |
| Date Published: | 2018-01-01 |
| Start Page: | 573 |
| End Page: | 583 |
| Language: | English |
| DOI: | 10.1007/978-3-319-64263-5_29 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Book Chapter 29 -- Export Date: 1 June 2018 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work